Home › Companies › ELDN

Pipeline (3 active programs)

Discontinued (1)

• tegoprubart — IgA Nephropathy · deprioritized; all IgAN clinical development activities were discontinued in 2023

Capital (as filed)

Cash

$6.8M cash and cash equivalents · Jun 30, 2026 (10-Q)

Short-term investments

$82.0M Jun 30, 2026

Operating cash flow

−$22.7M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$88.8M cash, runway Q2 2027 per the update of Sep 22, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

• 2026-09-23 UPDATE: Eledon Pharmaceuticals (ELDN) - The 24-Month Curves Keep Separating 🔒 Paid
• 2026-09-03 UPDATE: Eledon Pharmaceuticals (ELDN) - The Islet Program Grows Up 🔒 Paid
• 2026-08-14 Eledon Pharmaceuticals (ELDN) — Scientific Deep Dive for Tegoprubart and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Eledon Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-08-14 Watch Eledon Pharmaceuticals (ELDN) — Scientific Deep Dive for Tegoprubart and Pipeline Products Biology and tolerability differentiation are real but the kidney program advances on a missed primary endpoint, the Phase 3 NI margin is undisclosed, and the trial is unfunded behind a going-concern conclusion.
2. 2026-09-03 Watch UPDATE: Eledon Pharmaceuticals (ELDN) - The Islet Program Grows Up Islet IND filed converts the most under-modeled asset into a company-owned regulatory program, but the undisclosed NI margin, going-concern conclusion, and worsening dilution math keep the stance at Watch.
3. 2026-09-23 Watch UPDATE: Eledon Pharmaceuticals (ELDN) - The 24-Month Curves Keep Separating 24-month eGFR gap widened to 13 points with p<0.05 at three consecutive timepoints, firming the CNI-nephrotoxicity thesis, but the undisclosed NI margin and going-concern conclusion remain unresolved ahead of a mandatory raise.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (16)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Oct 26, 2026ReleaseEledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology
• Oct 5, 2026ReleaseEledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
• Sep 22, 2026ReleaseEledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society→ BD updateEledon just received FDA Fast Track Designation for tegoprubart and presented BESTOW extension data showing the eGFR advantage vs. tacrolimus growing to ~13 mL/min/1.73m² at month 24 with statistical significance — and zero rejections in the tegoprubart arm beyond month six. The three-point delta that underwhelmed at month 12 appears to be compounding, not fading.BD extracted 1 program update from this document → ELDN pipeline
• Sep 9, 2026ReleaseEledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
• Sep 3, 2026ReleaseEledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial→ BD updateEledon just checked one of my three explicit "add only on" boxes — the company-sponsored islet IND is filed — while simultaneously confirming Q4 2026 LEGACY Phase 3 initiation and opening compassionate-use programs in two new patient populations. The stock is down ~21% from my writeup price, which makes the timing matter.BD extracted 1 program update from this document → ELDN pipeline
• Aug 13, 2026ReleaseEledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlightsvia aggregator
• Aug 13, 20268-KCurrent report: results of operations · EX-99.1
• Aug 13, 202610-QQuarterly report
• Jun 22, 20268-KCurrent report: charter / bylaws / fiscal year, shareholder vote
• May 13, 20268-KCurrent report: results of operations · EX-99.1
• May 13, 202610-QQuarterly report
• May 1, 2026S-3Shelf registration
• Apr 30, 2026DEFA14AProxy soliciting material
• Apr 30, 2026DEF 14AProxy statement
• Mar 19, 20268-KCurrent report: results of operations · EX-99.1
• Mar 19, 202610-KAnnual report